TABLE 2.

Logistic Regression Predicting Whether Patients Received PET

Characteristic	OR	P	Global P
Race/ethnicity category
White NH (ref)			0.0044^*
Black NH vs. White NH	0.688 (0.54–0.88)	0.0023^*
Hispanic vs. White NH	0.958 (0.70–1.32)	0.7944
Other/unknown vs. White NH	0.752 (0.58–0.98)	0.0336^*
Patient region at diagnosis
West (ref)			0.0374^*
East vs. west	0.799 (0.67–0.95)	0.0111^*
Midwest vs. west	0.856 (0.70–1.05)	0.1390
South vs. west	0.996 (0.85–1.17)	0.9655
Derived AJCC stage group, sixth edition
Stage I (ref)			<0.0001^*
Stage II vs. stage I	0.880 (0.70–1.11)	0.2769
Stage III vs. stage I	0.695 (0.58–0.83)	<0.0001^*
Stage IVA vs. stage I	0.455 (0.38–0.55)	<0.0001^*
Initial treatment
RT (ref)			<0.0001^*
Chemotherapy vs. RT	0.625 (0.50–0.78)	<0.0001^*
Chemotherapy and RT vs. RT	0.827 (0.69–1.00)	0.0464^*
Chemotherapy and surgery vs. RT	1.337 (1.04–1.72)	0.0223^*
Chemotherapy, surgery, and RT vs. RT	0.969 (0.72–1.31)	0.8356
Surgery vs. RT	1.093 (0.90–1.33)	0.3676
Surgery and RT vs. RT	1.259 (0.83–1.92)	0.2843
Diagnostic imaging category
Any PET (ref)			0.0002^*
CT/CTA alone vs. any PET	0.673 (0.56–0.81)	<0.0001^*
No related imaging vs. any PET	1.178 (0.64–2.18)	0.6019
Histologic subtype of NSCLC
Adenocarcinoma (ref)			0.0183^*
Adenosquamous vs. adenocarcinoma	1.065 (0.72–1.57)	0.7528
Large cell carcinoma vs. adenocarcinoma	0.920 (0.62–1.35)	0.6718
Neuroendocrine vs. adenocarcinoma	0.576 (0.36–0.91)	0.0187^*
Squamous cell carcinoma vs. adenocarcinoma	1.176 (1.02–1.35)	0.0212^*
Other/not specified vs. adenocarcinoma	1.148 (0.95–1.39)	0.1537